Oils4cure: finding an effective drug to alleviate Refractory Epilepsy, one of the most severe symptoms in the pathology of Tuberous Sclerosis Complexbroad
oils4cure · Horizon Europe grant · 2023-12-01–2026-08-31
EC contribution
Total cost
Beneficiaries
About the data
Source: CORDIS (official EU open data), Horizon Europe. Framework HORIZON · call HORIZON-EIC-2023-ACCELERATOR-01 · scheme HORIZON-EIC-ACC-BF · topic HORIZON-EIC-2023-ACCELERATOROPEN-01. CORDIS record →
Objective
OILS4CURE is a Spanish biotech company dedicated to the research, development, production and commercialisation of medicinal products based on full spectrum medicinal cannabis extracts. It is developing a drug to manage refractory epilepsy associated with tuberous sclerosis complex (YCJ-01) and another for Leukodystrophies (YCJ-02), both paediatric rare diseases. This project only deals with the development of our first and most advanced therapy directed at tuberous sclerosis complex (TSC).
Beneficiaries (1)
| Organisation | Country | Role | EC contribution | SME |
|---|---|---|---|---|
| OILS4CURE SL | ES | coordinator | €1,557,877 | Yes |
Get the EU Defence Funding Calendar — free
The full calendar of open EU defence and dual-use funding calls, sorted by deadline, updated nightly. Delivered with DFM Analysis, our weekly briefing on who is funding what in European defence.
Or browse all open defence & dual-use calls on the funding calendar →
Defence Finance Monitor is an analytical and informational product. Grant data is official CORDIS; the paid Annual Professional subscription is handled on DFM Analysis.